Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants

British Journal of Clinical Pharmacology

Volumn 65, Issue 1, 2008, Pages 87-97

  Polasek, Thomas M ^a   Miners, John O ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

Cytochromes P450; Mechanism based inactivation; Nortriptyline; Time dependent inhibition; Tricyclic antidepressants

Indexed keywords

AMITRIPTYLINE; CLOMIPRAMINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DESIPRAMINE; IMIPRAMINE; NORCLOMIPRAMINE; NORTRIPTYLINE; PROTRIPTYLINE; RECOMBINANT PROTEIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; ESCHERICHIA COLI; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECTROSCOPY;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; MICROSOMES, LIVER; MODELS, BIOLOGICAL; NORTRIPTYLINE; TIME FACTORS; TISSUE CULTURE TECHNIQUES;

EID: 37249019565     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02964.x     Document Type: Article

References (47)

1. Alderman J, Greenblatt DJ, Allison J, Preskorn S, Harrison W, Chung M. Desipramine pharmacokinetics with the selective serotonin reuptake inhibitors (SSRIs), paroxetine or sertraline. In : American Psychiatric Association Sesquicentennial Celebration, 1844-1994, Philadelphia. 1994.
2. Barbhaiya RH, Buch AB, Greene DS. A study of the effect of age and gender on the pharmacokinetics of nerfazodone after single and multiple doses. J Clin Psychopharmacol 1996 16 : 19 25.
3. Perucca E, Richens A. Interaction between phenytoin and imipramine. Br J Clin Pharmacol 1977 4 : 485 6.
4. Richens A, Houghton GW. Effect of drug therapy on the metabolism of phenytoin. In : Clinical Pharmacology of Antiepileptic Drugs, eds Schineider H, Janz D, Gardnerd-Thorp C, Meinardi H, Sherwin AL. Berlin : Springer-Verlag 1975 : 87 95.
5. Baumann P, Meyer JW, Amey M, Baettig D, Bryois C, Jonzier-Perey M, Koeb L, Monney C, Woggon B. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther Drug Monit 1992 14 : 1 8.
6. Mayersohn M, Guentert TW. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacokinet 1995 29 : 292 332.
7. Ball SE, Ahern D, Scatina J, Kao J. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol 1997 43 : 619 26.
8. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of paroxetine and other 5-HT re-uptake inhibitors of cytochrome P450IID6 activity in human liver microsomes. Br J Clin Pharmacol 1991 32 : P658 P659.
9. Favreau LV, Palamanda JR, Lin C, Nomeir AA. Improved reliability of the rapid microtiter plate assay using recombinant enzyme in predicting CYP2D6 inhibition in human liver microsomes. Drug Metab Dispos 1999 27 : 436 9.
10. Hara Y, Nakajima M, Miyamato KI, Yokoi T. Inhibitory effects of psychotropic drugs on mexiletine metabolism in human liver microsomes. Prediction of in vivo drug interactions. Xenobiotica 2005 35 : 549 60.
11. Shin JG, Park JY, Kim MJ, Shon JH, Yoon YR, Cha IJ, Lee SS, Oh SW, Kim SW, Flockhart DA. Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos 2002 30 : 1102 7.
12. Yue QY, Säwe J. Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes. Eur J Clin Pharmacol 1997 52 : 41 7.
13. Kajita J, Inano K, Fuse E, Kuwabara T, Kobayashi H. Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities. Drug Metab Dispos 2002 30 : 1504 11.
14. Kent UM, Jushchyshyn MI, Hollenberg PF. Mechanism-based inactivators as probes of cytochrome P450 structure and function. Curr Drug Metab 2001 2 : 215 43.
15. Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, Zhang Q, Huang M, Xu A. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 2004 5 : 415 42.
16. McNeil CM, Murray M. Inhibition of microsomal cytochromes P450 in rat liver by the tricyclic antidepressant drug desipramine and its primary oxidized metabolites. Biochem Pharmacol 1996 51 : 15 20.
17. Murray M. Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. Mol Pharmacol 1992 42 : 931 8.
18. Murray M, Field SL. Inhibition and metabolite complexation of rat hepatic microsomal cytochrome P450 by tricyclic antidepressants. Biochem Pharmacol 1992 43 : 2065 71.
19. Bensoussan C, Delaforge M, Mansuy D. Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem Pharmacol 1995 49 : 591 602.
20. Roos PH. Common multiple interactions of tricyclic antidepressants and orphenadrine with liver microsomal cytochrome P450 enzymes of the rat. Xenobiotica 1999 29 : 629 40.
21. Murray M, Murray K. Mechanism-based inhibition of CYP activities in rat liver by fluoxetine and structurally similar alkylamines. Xenobiotica 2003 33 : 973 87.
22. Isobe T, Hichiya H, Hanioka N, Yamamoto S, Shinoda S, Funae Y, Satoh T, Yamano S, Narimatsu S. Different effects of desipramine on bufuralol 1′-hydroxylation by rat and human CYP2D enzymes. Biol Pharm Bull 2005 28 : 634 40.
23. Masubuchi Y, Igarashi S, Suzuki S, Horie T, Narimatsu S. Imipramine-induced inactivation of a cytochrome P450 2D enzyme in rat liver liver microsomes: in relation to covalent binding of its reactive metabolite. J Pharmacol Exp Ther 1996 279 : 724 31.
24. Polasek TM, Elliot DJ, Lewis BC, Miners JO. Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther 2004 311 : 996 1007.
25. Polasek TM, Elliot DJ, Somogyi AA, Gillam EM, Lewis BC, Miners JO. An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol 2006 61 : 570 84.
26. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan LS, Grimm SW, Kao J, King SP, Miwa G, Ni L, Kumar GN, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003 31 : 815 32.
27. Ghanbari K, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, Rostami-Hodjegan A. A critical evaluation of the experimental design of studies of mechanism-based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr Drug Metab 2006 7 : 315 34.
28. Sutton D, Butler AM, Nadin L, Murray M. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther 1997 282 : 294 300.
29. Alexanderson B. Pharmacokinetics of desmethylimipramine and nortriptyline in man after single and multiple oral doses - a cross-over study. Eur J Clin Pharmacol 1972 5 : 1 10.
30. Rudorfer MV, Potter WZ. Metabolism of tricyclic antidepressants. Cell Mol Neurobiol 1999 19 : 373 409.
31. Nielsen KK, Brøsen K, Hansen MG, Gram LF. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994 55 : 518 27.
32. McGinnity DF, Riley RJ. Predicting drug pharmacokinetics in humans from in vitro metabolism studies. Biochem Soc Trans 2001 29 : 135 9.
33. McGinnity DF, Griffin SJ, Moody GC, Voice M, Hanlon S, Friedberg T, Riley RJ. Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli. Drug Metab Dispos 1999 27 : 1017 23.
34. Andrews J, Abd-Ellah MF, Randolph NL, Kenworthy KE, Carlile DJ, Friedberg T, Houston JB. Comparative study of the metabolism of drug substrates by human cytochrome P450 3A4 expressed in bacterial, yeast and human lymphoblastoid cells. Xenobiotica 2002 32 : 937 47.
35. Moody GC, Griffin SJ, Mather AN, McGinnity DF, Riley RJ. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica 1999 29 : 53 75.
36. Crespi CL, Penman BW. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv Pharmacol 1997 43 : 171 88.
37. Zimmer R, Gieschke R, Fischbach R, Gasic S. Interaction studies with moclobemide. Acta Psychiatr Scand Suppl 1990 360 : 84 6.
38. Madeira M, Levine M, Chang TKH, Mirfazaelian A, Bellward GD. The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6. Drug Metab Dispos 2004 32 : 460 7.
39. Palamanda JR, Kumari P, Kim H, Nomeir AA. Mechanism-based inhibition of recombinant CYP2D6 but not human liver microsomal CYP2D6 by propranolol. Drug Metab Rev 2005 37 (Suppl. 2 257.
40. Silber BM, Holford NH, Riegelman S. Dose-dependent elimination of propranolol and its major metabolites in humans. J Pharm Sci 1983 72 : 725 32.
41. Somogyi A, Muirhead M. Pharmacokinetic interactions of cimetidine. Clin Pharmacokinet 1987 12 : 321 66.
42. Straka RJ, Lalonde RL, Pieper JA, Bottorff MB, Mirvis DM. Nonlinear pharmacokinetics of unbound propranolol after oral administration. J Pharm Sci 1987 76 : 521 4.
43. Estabrook RW, Franklin MR, Cohen B, Shigamatzu A, Hildebrant AG. Biochemical and genetic factors influencing drug metabolism. Influence of hepatic microsomal mixed function oxidation reactions on cellular metabolic control. Metabolism 1971 20 : 187 99.
44. Murray M. Drug-mediated inactivation of cytochrome P450. Clin Exp Pharmacol Physiol 1997 24 : 465 70.
45. Mansuy D, Rouer E, Bacot C, Gans P, Chottard JC, Leroux JP. Interaction of aliphatic N-hydroxylamines with microsomal cytochrome P450: nature of the different derived complexes and inhibitory effects on monoxygenases activities. Biochem Pharmacol 1978 27 : 1129 37.
46. Riley RJ, Roberts P, Kitteringham NR, Park BK. Formation of cytotoxic metabolites from phenytoin, imipramine, desipramine, amitriptyline and mianserin by mouse and human hepatic microsomes. Biochem Pharmacol 1990 39 : 1951 8.
47. Pirmohamed M, Kitteringham NR, Park BK. Idiosyncratic reactions to antidepressants: a review of the possible mechanisms and predisposing factors. Pharmacol Ther 1992 53 : 105 25.